141 related articles for article (PubMed ID: 19630815)
1. Regulation of platelet biogenesis: insights from the May-Hegglin anomaly and other MYH9-related disorders.
Chen Z; Shivdasani RA
J Thromb Haemost; 2009 Jul; 7 Suppl 1():272-6. PubMed ID: 19630815
[TBL] [Abstract][Full Text] [Related]
2. The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway.
Chen Z; Naveiras O; Balduini A; Mammoto A; Conti MA; Adelstein RS; Ingber D; Daley GQ; Shivdasani RA
Blood; 2007 Jul; 110(1):171-9. PubMed ID: 17392504
[TBL] [Abstract][Full Text] [Related]
3. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition.
Chen Y; Boukour S; Milloud R; Favier R; Saposnik B; Schlegel N; Nurden A; Raslova H; Vainchenker W; Balland M; Nurden P; Debili N
J Thromb Haemost; 2013 Dec; 11(12):2163-75. PubMed ID: 24165359
[TBL] [Abstract][Full Text] [Related]
4. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease.
Pal K; Nowak R; Billington N; Liu R; Ghosh A; Sellers JR; Fowler VM
Blood; 2020 May; 135(21):1887-1898. PubMed ID: 32315395
[TBL] [Abstract][Full Text] [Related]
5. Cloning of the murine non-muscle myosin heavy chain IIA gene ortholog of human MYH9 responsible for May-Hegglin, Sebastian, Fechtner, and Epstein syndromes.
D'Apolito M; Guarnieri V; Boncristiano M; Zelante L; Savoia A
Gene; 2002 Mar; 286(2):215-22. PubMed ID: 11943476
[TBL] [Abstract][Full Text] [Related]
6. Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets.
Pertuy F; Eckly A; Weber J; Proamer F; Rinckel JY; Lanza F; Gachet C; Léon C
Blood; 2014 Feb; 123(8):1261-9. PubMed ID: 24243973
[TBL] [Abstract][Full Text] [Related]
7. MYH9-related platelet disorders.
Althaus K; Greinacher A
Semin Thromb Hemost; 2009 Mar; 35(2):189-203. PubMed ID: 19408192
[TBL] [Abstract][Full Text] [Related]
8. Advances in the understanding of MYH9 disorders.
Kunishima S; Saito H
Curr Opin Hematol; 2010 Sep; 17(5):405-10. PubMed ID: 20601875
[TBL] [Abstract][Full Text] [Related]
9. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
Heath KE; Campos-Barros A; Toren A; Rozenfeld-Granot G; Carlsson LE; Savige J; Denison JC; Gregory MC; White JG; Barker DF; Greinacher A; Epstein CJ; Glucksman MJ; Martignetti JA
Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
[TBL] [Abstract][Full Text] [Related]
10. Defective expression of GPIb/IX/V complex in platelets from patients with May-Hegglin anomaly and Sebastian syndrome.
Di Pumpo M; Noris P; Pecci A; Savoia A; Seri M; Ceresa IF; Balduini CL
Haematologica; 2002 Sep; 87(9):943-7. PubMed ID: 12217806
[TBL] [Abstract][Full Text] [Related]
11. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation.
Pecci A; Malara A; Badalucco S; Bozzi V; Torti M; Balduini CL; Balduini A
Thromb Haemost; 2009 Jul; 102(1):90-6. PubMed ID: 19572073
[TBL] [Abstract][Full Text] [Related]
12. [Autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies and MYH9 disorders].
Kunishima S
Rinsho Byori; 2009 Apr; 57(4):365-70. PubMed ID: 19489439
[TBL] [Abstract][Full Text] [Related]
13. Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations.
Pecci A; Canobbio I; Balduini A; Stefanini L; Cisterna B; Marseglia C; Noris P; Savoia A; Balduini CL; Torti M
Hum Mol Genet; 2005 Nov; 14(21):3169-78. PubMed ID: 16162639
[TBL] [Abstract][Full Text] [Related]
14. Myosin-II repression favors pre/proplatelets but shear activation generates platelets and fails in macrothrombocytopenia.
Spinler KR; Shin JW; Lambert MP; Discher DE
Blood; 2015 Jan; 125(3):525-33. PubMed ID: 25395423
[TBL] [Abstract][Full Text] [Related]
15. Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease.
Marini M; Bruschi M; Pecci A; Romagnoli R; Musante L; Candiano G; Ghiggeri GM; Balduini C; Seri M; Ravazzolo R
Int J Mol Med; 2006 May; 17(5):729-36. PubMed ID: 16596254
[TBL] [Abstract][Full Text] [Related]
16. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation.
Eckly A; Strassel C; Freund M; Cazenave JP; Lanza F; Gachet C; Léon C
Blood; 2009 Apr; 113(14):3182-9. PubMed ID: 18984861
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias.
Balduini CL; Pecci A; Savoia A
Br J Haematol; 2011 Jul; 154(2):161-74. PubMed ID: 21542825
[TBL] [Abstract][Full Text] [Related]
18. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium.
Seri M; Cusano R; Gangarossa S; Caridi G; Bordo D; Lo Nigro C; Ghiggeri GM; Ravazzolo R; Savino M; Del Vecchio M; d'Apolito M; Iolascon A; Zelante LL; Savoia A; Balduini CL; Noris P; Magrini U; Belletti S; Heath KE; Babcock M; Glucksman MJ; Aliprandis E; Bizzaro N; Desnick RJ; Martignetti JA
Nat Genet; 2000 Sep; 26(1):103-5. PubMed ID: 10973259
[TBL] [Abstract][Full Text] [Related]
19. Historical hematology: May-Hegglin anomaly.
Saito H; Kunishima S
Am J Hematol; 2008 Apr; 83(4):304-6. PubMed ID: 17975807
[TBL] [Abstract][Full Text] [Related]
20. Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells.
Pecci A; Bozzi V; Panza E; Barozzi S; Gruppi C; Seri M; Balduini CL
Thromb Haemost; 2011 Oct; 106(4):693-704. PubMed ID: 21833445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
